119 related articles for article (PubMed ID: 21710494)
1. Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor.
Orengo AM; Fabbi M; Miglietta L; Andreani C; Bruzzone M; Puppo A; Cristoforoni P; Centurioni MG; Gualco M; Salvi S; Boccardo S; Truini M; Piazza T; Canevari S; Mezzanzanica D; Ferrini S
Int J Cancer; 2011 Sep; 129(5):1116-25. PubMed ID: 21710494
[TBL] [Abstract][Full Text] [Related]
2. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.
Carbotti G; Orengo AM; Mezzanzanica D; Bagnoli M; Brizzolara A; Emionite L; Puppo A; Centurioni MG; Bruzzone M; Marroni P; Rossello A; Canevari S; Ferrini S; Fabbi M
Int J Cancer; 2013 Jun; 132(11):2597-605. PubMed ID: 23169448
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer.
Pylväs M; Puistola U; Laatio L; Kauppila S; Karihtala P
Anticancer Res; 2011 Apr; 31(4):1411-5. PubMed ID: 21508394
[TBL] [Abstract][Full Text] [Related]
4. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.
Yigit R; Figdor CG; Zusterzeel PL; Pots JM; Torensma R; Massuger LF
Eur J Cancer; 2011 Aug; 47(12):1883-9. PubMed ID: 21514148
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
Nash MA; Lenzi R; Edwards CL; Kavanagh JJ; Kudelka AP; Verschraegen CF; Platsoucas CD; Freedman RS
Clin Exp Immunol; 1998 May; 112(2):172-80. PubMed ID: 9649178
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma.
Chen LL; Ye F; Lü WG; Yu Y; Chen HZ; Xie X
J Obstet Gynaecol Res; 2009 Apr; 35(2):212-8. PubMed ID: 19335794
[TBL] [Abstract][Full Text] [Related]
8. The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment.
Carbotti G; Barisione G; Orengo AM; Brizzolara A; Airoldi I; Bagnoli M; Pinciroli P; Mezzanzanica D; Centurioni MG; Fabbi M; Ferrini S
Clin Cancer Res; 2013 Sep; 19(17):4611-20. PubMed ID: 23873689
[TBL] [Abstract][Full Text] [Related]
9. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
[TBL] [Abstract][Full Text] [Related]
10. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells.
Wang ZY; Gaggero A; Rubartelli A; Rosso O; Miotti S; Mezzanzanica D; Canevari S; Ferrini S
Int J Cancer; 2002 Apr; 98(6):873-8. PubMed ID: 11948465
[TBL] [Abstract][Full Text] [Related]
11. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
Odunsi K; Wollman RM; Ambrosone CB; Hutson A; McCann SE; Tammela J; Geisler JP; Miller G; Sellers T; Cliby W; Qian F; Keitz B; Intengan M; Lele S; Alderfer JL
Int J Cancer; 2005 Feb; 113(5):782-8. PubMed ID: 15499633
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma.
Xie X; Ye D; Chen H; Lu W; Cheng B; Zhong H
Int J Gynaecol Obstet; 2004 May; 85(2):151-8. PubMed ID: 15099777
[TBL] [Abstract][Full Text] [Related]
14. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
[TBL] [Abstract][Full Text] [Related]
15. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer.
Schock H; Surcel HM; Zeleniuch-Jacquotte A; Grankvist K; Lakso HÅ; Fortner RT; Kaaks R; Pukkala E; Lehtinen M; Toniolo P; Lundin E
Endocr Relat Cancer; 2014; 21(6):831-44. PubMed ID: 25270324
[TBL] [Abstract][Full Text] [Related]
16. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
[TBL] [Abstract][Full Text] [Related]
17. Detection of epithelial ovarian-cancer-associated antigens involved in immune complexes by monoclonal antibodies.
Kawata M; Sekiya S
Tumour Biol; 1998; 19(1):1-11. PubMed ID: 9422077
[TBL] [Abstract][Full Text] [Related]
18. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
19. IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma.
Malekzadeh M; Dehaghani AS; Ghaderi A; Doroudchi M
Cancer Biomark; 2013 Jan; 13(6):417-25. PubMed ID: 24595078
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of IL-10 and TGF-β levels and myeloid and lymphoid dendritic cells in ovarian cancer patients.
Wertel I; Polak G; Tarkowski R; Kotarska M
Ginekol Pol; 2011 Jun; 82(6):414-20. PubMed ID: 21853929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]